Ultragenyx (RARE) Stock Looks Overvalued After Record Revenue Update

Ultragenyx Pharmaceutical stock has had a tough run over the past few years, yet current valuation checks do not frame it as an obvious bargain either. After a period of weak long term returns, the market now appears to be pricing Ultragenyx with a modestly expensive tilt based on standard multiples.

• Ultragenyx Pharmaceutical has declined 72.1% over the past 5 years, which raises the question of whether the share price now reflects the company’s progress or if sentiment has simply reset lower.
• The company is working toward profitability and preparing potential new product launches, while investors still face execution risk around those launches and future regulatory outcomes that can affect how much growth is ultimately realised.
• The stock earns a mixed valuation read, with a value score of 4 out of 6 checks, which points to a valuation picture that is neither clearly cheap nor clearly expensive.

The issue now is whether Ultragenyx Pharmaceutical’s current price fairly reflects those mixed signals or leaves investors paying too much for the potential ahead.

Find out why Ultragenyx Pharmaceutical’s -5.9% return over the last year is lagging behind its peers.

Does Ultragenyx Pharmaceutical Look Pricey on Sales?

P/S is often a better fit for a company like Ultragenyx Pharmaceutical that is still reporting losses and is working toward profitability, because it anchors valuation to current revenue instead of earnings.

Ultragenyx Pharmaceutical currently trades on a P/S of 3.6x, compared with an average of 11.8x for the broader biotechs industry and 6.4x across directly comparable peers. On Simply Wall St’s fair P/S estimate of 2.6x, which blends factors such as margins, risk and scale, the stock sits at a premium to where that model would place it. The fair multiple is lower than both peers and the sector, which suggests the framework is applying a discount for the company specific risk profile.

Despite the recent news about record quarterly revenue and preparations for potential gene therapy launches, the current 3.6x P/S still screens above the tailored fair P/S benchmark of 2.6x.

On the P/S multiple, Ultragenyx Pharmaceutical currently appears expensive relative to the fair ratio implied by its risk and business profile.

See what the numbers say about this price — find out in our valuation breakdown.

The Ultragenyx Pharmaceutical Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives for Ultragenyx Pharmaceutical pick up where this valuation puzzle leaves off. They spell out which combinations of future growth, margins and earnings would need to hold for the stock to be worth materially more or materially less than today’s price, based on scenarios discussed on the company’s Community page. Each Narrative sets out a fair value as a specific thesis about Ultragenyx Pharmaceutical’s business that you can revisit over time as new information emerges.

One of the top community narratives on Ultragenyx Pharmaceutical: roughly fairly valued

“Ultragenyx has phenomenal science, but its commercial execution is a cash-incinerating treadmill…”

Read one of the top narratives on Ultragenyx Pharmaceutical

Do you think there’s more to the story for Ultragenyx Pharmaceutical? Head over to our Community to see what others are saying!

The Bottom Line

Ultragenyx Pharmaceutical appears mildly overvalued on its current P/S multiple compared with the tailored fair ratio that reflects its risk and business profile. That leaves less obvious valuation upside unless the company delivers stronger than expected commercial progress from its pipeline and moves more clearly toward sustainable profitability. For investors, the key question is whether Ultragenyx Pharmaceutical can translate its science and upcoming launch efforts into durable revenue and margin improvements that justify paying a premium today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com